In contrast, in our study, we show that IL-36α levels in patients with stage G3 ovarian cancer are present at high serum levels compared to the reference group, patients with stage G1 and G2 ovarian cancer (where p<0.001), which may indicate a pro-tumor role for IL-36α in this case. Here, IL36A is linked to ovarian cancer.